• Avalo Therapeutics CFO Christopher Ryan Sullivan exercised stock options for 10,185 common shares at USD 8.04 on Sept. 10.
• He sold 10,185 common shares at USD 17.62, cutting his direct stake to 39,900 shares.
• Derivative holdings fell to 105,815 stock options following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001810417-26-000021), on September 11, 2026, and is solely responsible for the information contained therein.